Indeed, there are already 11 percent of respondents currently selling biosimilars to their own biologic. And of the 41 percent of respondents who are currently considering biosimilars for their pipeline, 17 percent of them would consider creating a biosimilar version of their own molecule. The end goal for this strategy would be to corner the market share for that specific product, and it wouldn’t be the first time we’ve seen such efforts undertaken. After all, in the small molecule space, a number of companies made investments in creating a generic version of their own drug.Read more at Biosimilar Development.
Editor Anna Rose Welch at Biosimilar Development speaks to VP of Industry Standard Research Kate Hammeke about our recent report Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition).